Jos Jonkers

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 278 publications

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Journal: Science translational medicine

Published: March 18, 2026

Corrigendum to Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Corrigendum to Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Journal: The Journal of clinical investigation

Published: March 02, 2026

Defective BRCA1-mediated DNA end resection drives tandem duplication formation and FANCM synthetic lethality.

Defective BRCA1-mediated DNA end resection drives tandem duplication formation and FANCM synthetic lethality.

Journal: bioRxiv : the preprint server for biology

Published: February 27, 2026

Beyond the traditional dish: advanced 3D ex vivo culture platforms for tumor modelling.

Beyond the traditional dish: advanced 3D ex vivo culture platforms for tumor modelling.

Journal: Seminars in cancer biology

Published: February 21, 2026

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 06, 2026

FGFR rearrangements: oncogenic drivers and therapeutic targets.

FGFR rearrangements: oncogenic drivers and therapeutic targets.

Journal: Trends in cancer

Published: December 11, 2025

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 20, 2025

BRCA1 deficiency leads to aberrant epithelial differentiation in the thymus.

BRCA1 deficiency leads to aberrant epithelial differentiation in the thymus.

Journal: ImmunoHorizons

Published: September 25, 2025

Insights from three decades of BRCA1/2 modeling in mice.

Insights from three decades of BRCA1/2 modeling in mice.

Journal: Nature genetics

Published: September 09, 2025

A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.

A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.

Journal: Mammalian genome : official journal of the International Mammalian Genome Society

Published: August 01, 2025

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Journal: NPJ breast cancer

Published: June 30, 2025

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

Journal: Nature communications

Published: June 18, 2025

Showing 1-12 of 278

Last Updated: 09/26/2026